TY - JOUR
T1 - Development of a core outcome set for clinical trials in non-infectious uveitis of the posterior segment
AU - COSUMO Working Group
AU - Tallouzi, Mohammad O.
AU - Mathers, Jonathan M.
AU - Moore, David J.
AU - Bucknall, Nicholas
AU - Calvert, Melanie J.
AU - Murray, Philip I.
AU - Denniston, Alastair K.
AU - Okada, Annabelle
AU - Vasconcelos-Santos, Daniel
AU - Jabs, Douglas A.
AU - Davis, Janet
AU - Smith, Justine
AU - Zierhut, Manfred
AU - Smet, Marc D. de
AU - Maese, David
AU - Hollis, Gaynor M.
AU - Roberts, Graham
AU - Emerson, Joanna
AU - Quigley, Joseph
AU - Cave, Katie
AU - Twigge, Kenneth
AU - McCarthy, Maxine
AU - Davis, Ruth
AU - Twigge, Eileen
AU - Roberts, Helen
AU - Emerson, Martin
AU - Maese, Racheal
AU - Mohammed, Bashar
AU - Bunce, Catey
AU - Damato, Erika
AU - Stanford, Miles
AU - Poonit, Natraj
AU - Lee, Richard
AU - Sharma, Srilakshmi M.
N1 - Funding Information:
This article represents an independent research project funded by the NIHR under the Program Clinical Doctoral Research Fellowship Scheme at the University of Birmingham (CDRF-2014-05-057). The views and opinions expressed by authors in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Publisher Copyright:
© 2021 American Academy of Ophthalmology
PY - 2021/8
Y1 - 2021/8
N2 - Purpose: To develop an agreed upon set of outcomes known as a “core outcome set” (COS) for noninfectious uveitis of the posterior segment (NIU-PS) clinical trials. Design: Mixed-methods study design comprising a systematic review and qualitative study followed by a 2-round Delphi exercise and face-to-face consensus meeting. Participants: Key stakeholders including patients diagnosed with NIU-PS, their caregivers, and healthcare professionals involved in decision-making for patients with NIU-PS, including ophthalmologists, nurse practitioners, and policymakers/commissioners. Methods: A long list of outcomes was developed based on the results of (1) a systematic review of clinical trials of NIU-PS and (2) a qualitative study of key stakeholders including focus groups and interviews. The long list was used to generate a 2-round Delphi exercise of stakeholders rating the importance of outcomes on a 9-point Likert scale. The proportion of respondents rating each item was calculated, leading to recommendations of “include,” “exclude,” or “for discussion” that were taken to a face-to-face consensus meeting of key stakeholders at which they agreed on the final COS. Main Outcome Measure: Items recommended for inclusion in the COS for NIU-PS. Results: A total of 57 outcomes grouped in 11 outcome domains were presented for evaluation in the Delphi exercise, resulting in 9 outcomes directly qualifying for inclusion and 15 outcomes being carried forward to the consensus meeting, of which 7 of 15 were agreed on for inclusion. The final COS contained 16 outcomes organized into 4 outcome domains comprising visual function, health-related quality of life, treatment side effects, and disease control. Conclusions: This study builds on international work across the clinical trials community and our qualitative research to construct the world's first COS for NIU-PS. The COS provides a list of outcomes that represent the priorities of key stakeholders and provides a minimum set of outcomes for use in all future NIU-PS clinical trials. Adoption of this COS can improve the value of future uveitis clinical trials and reduce noninformative research. Some of the outcomes identified do not yet have internationally agreed upon methods for measurement and should be the subject of future international consensus development.
AB - Purpose: To develop an agreed upon set of outcomes known as a “core outcome set” (COS) for noninfectious uveitis of the posterior segment (NIU-PS) clinical trials. Design: Mixed-methods study design comprising a systematic review and qualitative study followed by a 2-round Delphi exercise and face-to-face consensus meeting. Participants: Key stakeholders including patients diagnosed with NIU-PS, their caregivers, and healthcare professionals involved in decision-making for patients with NIU-PS, including ophthalmologists, nurse practitioners, and policymakers/commissioners. Methods: A long list of outcomes was developed based on the results of (1) a systematic review of clinical trials of NIU-PS and (2) a qualitative study of key stakeholders including focus groups and interviews. The long list was used to generate a 2-round Delphi exercise of stakeholders rating the importance of outcomes on a 9-point Likert scale. The proportion of respondents rating each item was calculated, leading to recommendations of “include,” “exclude,” or “for discussion” that were taken to a face-to-face consensus meeting of key stakeholders at which they agreed on the final COS. Main Outcome Measure: Items recommended for inclusion in the COS for NIU-PS. Results: A total of 57 outcomes grouped in 11 outcome domains were presented for evaluation in the Delphi exercise, resulting in 9 outcomes directly qualifying for inclusion and 15 outcomes being carried forward to the consensus meeting, of which 7 of 15 were agreed on for inclusion. The final COS contained 16 outcomes organized into 4 outcome domains comprising visual function, health-related quality of life, treatment side effects, and disease control. Conclusions: This study builds on international work across the clinical trials community and our qualitative research to construct the world's first COS for NIU-PS. The COS provides a list of outcomes that represent the priorities of key stakeholders and provides a minimum set of outcomes for use in all future NIU-PS clinical trials. Adoption of this COS can improve the value of future uveitis clinical trials and reduce noninformative research. Some of the outcomes identified do not yet have internationally agreed upon methods for measurement and should be the subject of future international consensus development.
KW - Clinical trials
KW - Consensus method
KW - Core outcome set
KW - Delphi technique/exercise
KW - Domain
KW - Key stakeholders
KW - Macular edema
KW - Outcomes
KW - Uveitis
UR - http://www.scopus.com/inward/record.url?scp=85103264221&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2021.01.022
DO - 10.1016/j.ophtha.2021.01.022
M3 - Article
SN - 0161-6420
VL - 128
SP - 1209
EP - 1221
JO - Ophthalmology
JF - Ophthalmology
IS - 8
ER -